The following is presented as part of The Columbian’s Opinion content, which offers a point of view in order to provoke thought and debate of civic issues. Opinions represent the viewpoint of the author. Unsigned editorials represent the consensus opinion of The Columbian’s editorial board, which operates independently of the news department.
Harrop: Americans are the real suckers on drug prices
By Froma Harrop
Published: January 20, 2019, 6:01am
Share:
Drugmakers rang in the new year by raising prices on hundreds of products — American prices, that is. Americans focused on the celebrations weren’t paying attention.
Allergan led the parade, hiking its prices by 10 percent on more than two dozen drugs. But note this: It didn’t raise the price of Botox, the anti-wrinkle treatment. Why? Because most users of Botox pay for it out of pocket. They can say, “I’m not bearing the extra freight. I think I’ll go another few months with crow’s-feet.”
Markets in which buyers and sellers haggle can bring reason to prices. Pharmaceuticals are special because when deemed essential to medical treatment, insurance covers them. The patient doesn’t get the full bill. Who pays? The people buying the insurance, whether private or government. That means employers pay, other buyers of private coverage pay and the taxpayers pay. There’s little in the way of a market check.
That’s why other governments have taken it upon themselves to negotiate the prices their people will pay for drugs. With a few exceptions, our government does not. Thus, a prescription for the much-advertised Humira, which treats psoriatic arthritis, costs only an average of $822 in Switzerland but $2,669 here.
The 2003 Medicare drug benefit — that is, the creation of Medicare Part D — was a product of George W. Bush’s administration and a Republican Congress. It specifically forbade the government to negotiate drug prices for Medicare. The drug plans in Part D do temper prices somewhat, but Medicare could do a lot better.
Donald Trump the candidate backed letting Medicare negotiate with drugmakers. Trump the president promptly dropped it. And whom did he name as the secretary of Health and Human Services but Alex Azar, a former top executive at Eli Lilly.
Last fall, Trump announced a project whereby Medicare Part B would use an “international pricing index” as a benchmark for setting prices for medications. Part B covers drugs administered by doctors and hospitals.
Bargaining ideas
The idea could have promise. But it wasn’t announced till right before the midterm elections and hasn’t been talked about much since. Not a good sign.
Several states are taking the matter into their own hands. Vermont is considering a program that would enable its residents to buy cheaper drugs from Canada. Olympia Snowe, a former Republican senator from Maine, made this a trademark proposal for addressing the high cost of drugs.
What these schemes have in common with Trump’s “international pricing index” is that they ask other countries to do the price bargaining for America. They pass the buck, our bucks.
The drug companies say that if Americans don’t cough up what they demand, they can’t afford the research to develop new products. In truth, drugmakers on average spend only 17 percent of their budgets on research and development. And nearly every new drug approved by the Food and Drug Administration started in research in government or university labs.
Sadly, when it comes to addressing the exorbitant prices Americans pay for their drugs, Trump talks a bigger game than he plays. We could be in for a surprise, but with a former Big Pharma executive running the HHS, don’t bet on it.
Morning Briefing Newsletter
Get a rundown of the latest local and regional news every Mon-Fri morning.
